Spero Therapeutics licenses Innovent antibody in deal worth up to $1.1B

July 14, 2026 6:00 AM

Innovent Biologics (01801.HK) and Spero Therapeutics (Nasdaq: SPRO) announced an exclusive license agreement for IBI355, a third-generation Fc-silent anti-CD40L antibody ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found